November 27, 2022
Ursula A. Matulonis, MD, spoke about the next steps for mirvetuximab soravtansine in the treatment of patients with folate receptor α–high platinum-resistant ovarian cancer.
November 22, 2022
Ursula A. Matulonis, MD, discussued studies are being conducted assessing the use of mirvetuximab soravtansine in patients with folate receptor-α–positive platinum-resistant ovarian cancer.
November 16, 2022
Ursula A. Matulonis, MD, indicated that acknowledgement of external targets such as FR-α could lead to success with antibody-drug conjugates in platinum-resistant ovarian cancer.
November 15, 2022
Ursula A. Matulonis, MD, spoke about the phase 3 SORAYA trial and how it helped lead to the approval of mirvetuximab soravtansine in folate receptor-α–positive platinum-resistant ovarian cancer.
October 26, 2022
At 2022 IGCS, Ursula A. Matulonis, MD, spoke about the toxicity profile observed with mirvetuximab soravtansine monotherapy in patients with folate receptor α–high platinum-resistant ovarian cancer reported from the phase 3 SORAYA study.
October 22, 2022
Ursula A. Matulonis, MD, spoke about the updated results of the phase 3 SORAYA trial with mirvetuximab soravtansine in patients with folate receptor α–high platinum-resistant ovarian cancer presented at 2022 IGCS.
October 12, 2022
Ursula A. Matulonis, MD, spoke about the motivation behind the phase 3 SORAYA trial investigating mirvetuximab soravtansine in patients with folate receptor α–high platinum-resistant ovarian cancer.
April 28, 2022
Ursula A. Matulonis, MD, speaks to potential future uses of mirvetuximab soravtansine in ovarian cancer.
April 22, 2022
In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.
April 14, 2022
Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.